Getinge 2022 Annual Report
Getinge 2022 Annual Report
Introduction
Strategy
Corporate Governance
Annual Report
Sustainability Report
Other information
Contents
Acute Care Therapies
Acute Care Therapies offers
world-leading products for life
support and therapies in acute
health conditions. The offering
includes solutions for:
• Critical care
•
Cardiac and vascular surgery
• Cardiopulmonary
• Vascular interventions
Customers' needs
Acute Care Therapies contributes to saving 10 million lives every
year. The need to save lives and reduce long-term complications
requires innovative and sustainable solutions and the right
combination of technologies and equipment for unique care
environments. Getinge works together with customers to develop
advanced clinical solutions and spread knowledge that can
contribute to improved therapy results, achieving more rapid
recovery and enhancing quality of life for patients in intensive care
and surgery.
Research and development
Acute Care Therapies continues to invest in research and develop-
ment (R&D), partly through securing resources that can contribute
to innovative R&D in the product segments with favorable future
prospects, and Acute Care Therapies has a leading position in this
regard. This includes, for example, ICU ventilators and products
for ECMO treatment in the field of cardiopulmonary support, with
the development of products, consumables, services and software
still considered as top priorities. A focal point is also supporting
customers with digital solutions such as clinical decision-making
support and efficient service.
Production sites
Acute Care Therapies' production sites are located in the US,
Germany, France, Sweden, Türkiye and China. In 2022, production
capacity increased in anesthesia, vascular grafts and solutions
for advanced monitoring and endoscopic vessel harvesting (EVH).
During the year, solar panels were installed in the production sites
in Suzhou and Antalya with the aim to become carbon neutral in
own operations by 2025.
Sales and profitability
Organic sales and profitability for 2022 declined compared with
2021, which was characterized by strong demand related to the
COVID-19 pandemic. In addition to lower demand, sales were
inhibited by supply chain challenges. Lower sales and supply
chain disruptions had a negative impact on the operating margin
compared with the preceding year.
17View entire presentation